Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy

Clin Nucl Med. 2024 May 1;49(5):454-456. doi: 10.1097/RLU.0000000000005137. Epub 2024 Mar 6.

Abstract

Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Humans
  • Lutetium*
  • Neuroendocrine Tumors* / diagnostic imaging
  • Neuroendocrine Tumors* / radiotherapy
  • Octreotide / adverse effects
  • Organometallic Compounds* / adverse effects
  • Positron-Emission Tomography*
  • Radioisotopes
  • Radionuclide Imaging*
  • Radiopharmaceuticals
  • Receptors, Peptide

Substances

  • copper dotatate CU-64
  • Radiopharmaceuticals
  • Octreotide
  • Lutetium-177
  • Radioisotopes
  • Receptors, Peptide
  • Organometallic Compounds
  • Lutetium